solifenacin   Click here for help

GtoPdb Ligand ID: 7483

Synonyms: Vesicare® | YM-67905 | YM-905
Approved drug
solifenacin is an approved drug (FDA (2004), UK (2009))
Compound class: Synthetic organic
Comment: The marketed formulation contains solifenacin succinate (PubChem CID 216457).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: solifenacin

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 32.78
Molecular weight 362.2
XLogP 3.57
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(N1CCc2c(C1c1ccccc1)cccc2)OC1CN2CCC1CC2
Isomeric SMILES O=C(N1CCc2c([C@@H]1c1ccccc1)cccc2)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
1. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K. (2002)
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Naunyn Schmiedebergs Arch Pharmacol, 366 (2): 97-103. [PMID:12122494]
2. Naito R, Yonetoku Y, Okamoto Y, Toyoshima A, Ikeda K, Takeuchi M. (2005)
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
J Med Chem, 48 (21): 6597-606. [PMID:16220976]
3. Prat M, Buil MA, Fernández MD, Castro J, Monleón JM, Tort L, Casals G, Ferrer M, Huerta JM, Espinosa S et al.. (2011)
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
Bioorg Med Chem Lett, 21 (11): 3457-61. [PMID:21524581]
4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A et al.. (2010)
AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
Br J Pharmacol, 160 (5): 1119-27. [PMID:20590605]